G-quadruplex ligands as potent regulators of lysosomes

Autophagy. 2023 Jul;19(7):1901-1915. doi: 10.1080/15548627.2023.2170071. Epub 2023 Feb 5.

Abstract

Guanine-quadruplex structures (G4) are unusual nucleic acid conformations formed by guanine-rich DNA and RNA sequences and known to control gene expression mechanisms, from transcription to protein synthesis. So far, a number of molecules that recognize G4 have been developed for potential therapeutic applications in human pathologies, including cancer and infectious diseases. These molecules are called G4 ligands. When the biological effects of G4 ligands are studied, the analysis is often limited to nucleic acid targets. However, recent evidence indicates that G4 ligands may target other cellular components and compartments such as lysosomes and mitochondria. Here, we summarize our current knowledge of the regulation of lysosome by G4 ligands, underlying their potential functional impact on lysosome biology and autophagic flux, as well as on the transcriptional regulation of lysosomal genes. We outline the consequences of these effects on cell fate decisions and we systematically analyzed G4-prone sequences within the promoter of 435 lysosome-related genes. Finally, we propose some hypotheses about the mechanisms involved in the regulation of lysosomes by G4 ligands.

Keywords: Autophagy; TFEB; guanine-quadruplex; lysosome membrane permeabilization; transcriptional regulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy*
  • DNA / metabolism
  • G-Quadruplexes*
  • Guanine
  • Humans
  • Ligands

Substances

  • Ligands
  • DNA
  • Guanine

Grants and funding

L.F is supported by a doctoral fellowship from the Ecole Doctorale Paris-Saclay. K.A.-V. is supported by the Mexican National Council of Science and Technology (CONACYT, funding #757821) and by La Ligue contre le Cancer (#TDKR23951). This work was supported by funds from the Institut National de la Santé et de la Recherche Médicale (INSERM). This study was funded by Agence National de la Recherche (ANR) grant (R21181DD) to M.D-M., ANR G4Access (ANR-20-CE12-0023) and INCa G4Access grants to J.L.M. and Chinese Scholarship Council (201906340018) to Y.L., the SYMBIT project Reg. no. CZ.02.1.01/0.0/0.0/15_003/0000477 financed from the ERDF, and the Czech Science Foundation (No. 22-21903S) to V.B. GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001